Effect of Low Positive End of Treatment Viral Load with Direct-Acting Antiviral Therapy on Sustained Virologic Response
| Autor: | Jena Mann, Apurva A. Modi, Vabhave Pal, Nirupama Ancha |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Cirrhosis Article Subject Sustained Virologic Response Hepatitis C virus RC799-869 Hepacivirus medicine.disease_cause Gastroenterology Antiviral Agents 03 medical and health sciences 0302 clinical medicine Internal medicine Chart review Medicine Humans Retrospective Studies Hepatology business.industry Antiviral therapy General Medicine Diseases of the digestive system. Gastroenterology Hepatitis C Chronic Viral Load medicine.disease 030104 developmental biology Virologic response 030211 gastroenterology & hepatology business Viral load Direct acting Research Article |
| Zdroj: | Canadian Journal of Gastroenterology & Hepatology Canadian Journal of Gastroenterology and Hepatology, Vol 2020 (2020) |
| ISSN: | 2291-2797 |
| Popis: | Background. Direct-acting antivirals (DAAs) are highly effective treatments against hepatitis C virus (HCV), with sustained virologic response (SVR) rates of 93–100% against all genotypes. In most patients, viral load (VL) becomes undetectable four weeks into treatment, but rarely a low positive VL may be observed at the end of treatment (EOT). This study was conducted to determine the effect of low positive EOT VLs with DAA therapies on SVR at 12 and 24 weeks. Methods. A retrospective chart review was conducted from January 2014 to December 2018 on 1256 HCV patients of all genotypes (1–6) who had received DAA therapy at two large hepatology referral centers. Baseline demographic data, along with VL at week four, EOT, and SVR12/24 time points were collected for patients that had positive EOT VL. Treatment outcome for any patient with positive EOT VL was noted. Results. Eight out of 1256 patients treated with varying DAA therapies were observed to have low positive EOT VLs ranging from Conclusion. In the DAA treatment era, low levels of detectable HCV RNA at EOT does not predict treatment failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text